Jun 16, 2020 12:44 PM IST Rakesh Radheshyam Jhunjhunwala held 4.41 percent stake (or 70.25 lakh equity shares) in the pharma company as per March shareholding pattern available on exchanges.
Jun 14, 2020 03:51 PM IST Anand Rathi is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 867 in its research report dated June 12, 2020.
Jun 02, 2020 11:30 AM IST Prabhudas Lilladher recommended Hold rating on Jubilant Life Sciences with a target price of Rs 414 in its research report dated Jun 01, 2020.
Jun 02, 2020 09:31 AM IST Jun 02, 2020 09:31 AM IST 
Jun 02, 2020 08:46 AM IST ICICI Direct is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 550 in its research report dated Jun 01, 2020.
Jun 01, 2020 03:21 PM IST Motilal Oswal is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 515 in its research report dated May 30, 2020.
May 29, 2020 08:39 PM IST Consolidated revenue from operations stood at Rs 2,391.41 crore for the quarter under consideration as against Rs 2,385.58 crore for the same period year ago, it added.
May 12, 2020 09:10 PM IST Under the licencing agreement, the company has the right to receive technology transfer of the Gilead manufacturing process to scale up production.
Apr 21, 2020 01:14 PM IST In December quarter, he held 3.45 percent stake in the company, which meant the shareholding increased by 0.96 percent during the March quarter.
Feb 04, 2020 09:29 AM IST Feb 04, 2020 09:22 AM IST 
Jan 31, 2020 05:00 PM IST Net sales during the quarter under review stood at Rs 2,279.89 crore, down 3.11 per cent, as against Rs 2,353.08 crore in the corresponding period a year ago.
Nov 18, 2019 08:42 PM IST Promoter entity sold shares at a price of Rs 493 per share, as per bulk deals data available on the BSE website.
Jul 30, 2019 08:13 PM IST Rakesh Radheshyam Jhunjhunwala already held 1.90 percent stake in Jubilant as per shareholding pattern of June 2019.
Jul 29, 2019 05:19 PM IST HDFC Securities is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 845 in its research report dated July 29, 2019.
Jul 26, 2019 05:45 PM IST Consolidated total revenue from operations, however, rose to Rs 2,181.86 crore for the quarter under consideration as against Rs 2,078.65 crore in the same period a year ago.
Jul 26, 2019 03:31 PM IST Jul 26, 2019 03:31 PM IST 
Jul 12, 2019 05:12 PM IST Net Sales are expected to increase by 13 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 2,348.5 crore, according to Prabhudas Lilladher.
Jul 03, 2019 10:26 AM IST Jubilant Life's performance would be driven by market share gains in key radiopharmaceutical products, a ramp-up in CMO business, capacity additions in finished dosages & Life Science Chemical segment and opportunities from the supply of ethanol to government, IDBI Capital said
Jun 11, 2019 04:36 PM IST Motilal Oswal is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 800 in its research report dated May 18, 2019.
Jun 04, 2019 03:52 PM IST HDFC Securities is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 915 in its research report dated May 19, 2019.
May 29, 2019 10:02 PM IST ICICI Direct recommended is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 710 in its research report dated May 20, 2019.
May 23, 2019 11:12 PM IST Dolat Capital is bullish on Jubilant Life Sciences has recommended Buy rating on the stock with a target price of Rs 750 in its research report dated May 21, 2019.
